Result of the week: CSL Limited

Hugh Dive

Atlas Funds Management

In our opinion, the result of the week was biotherapeutics company CSL’s half year results. Whilst the headline numbers were pre-announced in January, the granular details provided the market with greater confidence that CSL’s growth story will continue to deliver in the medium term.


Key highlights for us was the +18% growth in plasma products and that the flu vaccine business is on track to break even in 2018. CSL’s competitors have entered 2017 with supply issues, which normally will take 2-3 years to rectify, which should afford CSL 2-3 years of solid price increases.


Less than a month ago, it was trading below $100 and whilst it has rallied on the back of profit upgrade in late January and the results this week, this is one growth stock for investors to keep on a watch list if it drifts down over the course of the year as it has in the past few years.


1 stock mentioned

Hugh Dive
Chief Investment Officer
Atlas Funds Management

Atlas is a boutique investment manager focused on generating regular income for pension and SMSFs investors. Atlas' High Income Property Fund (ASX:AFM01) provides quarterly income with low volatility. Click follow to be the first to get my next wire

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.